We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Anticancer therapy: boosting the bang of Bim.
- Authors
Hendrickson, Andrea Wahner; Xue Wei Meng; Kaufmann, Scott H.; Meng, Xue Wei
- Abstract
Even though activating mutations of B-Raf, a kinase atop the MAPK signaling cascade, reportedly sensitize tumor cells to MEK inhibitors, Raf and MEK inhibitors have exhibited limited clinical activity. In this issue of the JCI, Cragg et al. report that MEK inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article beginning on page 3651). These findings illustrate the potential benefit of simultaneously inhibiting oncogenic kinases and inhibiting Bcl-2 action in solid tumors.
- Subjects
NEUROENDOCRINE tumors; CANCER cells; TUMORS; PATHOLOGY; TRANSPLANTATION of organs, tissues, etc.; CELLULAR pathology
- Publication
Journal of Clinical Investigation, 2008, Vol 118, Issue 11, p3582
- ISSN
0021-9738
- Publication type
journal article
- DOI
10.1172/JCI37553